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Increased expression of ACE2,
the SARS-CoV-2 entry receptor,
in alveolar and bronchial epithelium
of smokers and COPD subjects
To the Editor:
Angiotensin-converting enzyme 2 (ACE2) has been identified as the cell entry receptor used by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. Importantly, smokers and patients with
COPD are at an increased risk of severe complications and a higher mortality upon SARS-CoV-2 infection
[3]. We hypothesised that ACE2 expression is increased in lungs of smokers and patients with COPD,
which may at least partially explain their higher risk of a more severe course of coronavirus disease 2019
(COVID-19). Therefore, we aimed to investigate the expression of ACE2 on both mRNA and protein level
in a large number of lung tissue specimens of well-phenotyped subjects, including never-smokers, current
smokers without airflow limitation, and patients with COPD.
In this cross-sectional observational study, we analysed lung tissue specimens from 134 subjects from our
large lung tissue biobank at Ghent University Hospital (Ghent, Belgium) and from explant lungs from
end-stage COPD patients collected at UZ Gasthuisberg Leuven (Leuven, Belgium). Ex-smoking was
defined as smoking cessation for ⩾1 year. COPD severity was defined according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) classification. Written informed consent was obtained from all
subjects, and the study was approved by the medical ethical committees of Ghent University Hospital
(2016/0132; 2019/0537) and the University Hospital Gasthuisberg Leuven (S51577).
RNA extraction from lung tissue blocks of 120 subjects was performed with the miRNeasy Mini kit
(Qiagen, Hilden, Germany). Next, cDNA was prepared with the EvoScript Universal cDNA Master Kit
(Roche, Basel, Switzerland), followed by reverse transcriptase (RT)-qPCR analysis for ACE2 and 3
reference genes, as described previously [4, 5].
Sections from formalin-fixed paraffin-embedded lung tissue blocks of 87 subjects were stained for ACE2.
After antigen retrieval with citrate buffer (Scytek, West Logan, UT, USA), the slides were incubated with
anti-ACE2 antibody (polyclonal rabbit-anti-human, Abcam ab15248). Next, slides were coloured with
diaminobenzidine (Dako, Carpinteria, CA, USA) and counterstained with Mayer’s haematoxylin
(Sigma-Aldrich, St Louis, MO, USA). Quantitative measurements of the ACE2-positive signal in alveolar
tissue and bronchial epithelium were performed on images of stained paraffin sections as described
previously [6].
Statistical analysis was performed using Sigma Stat software (SPSS 26.0, Chicago, IL, USA) and R3.5.1,
using Kruskal–Wallis tests (on all six groups) followed by Mann–Whitney U-tests (for the comparison
between two groups), and multivariable linear regression analyses.
Using RT-PCR, ACE2 mRNA levels were determined in lung tissue from 120 subjects. ACE2 mRNA
expression was significantly higher in the lung tissue of current smokers without airflow limitation and
current smokers with COPD (GOLD stages II and III–IV) compared with never-smokers (figure 1a). In
addition, ex-smokers without airflow limitation showed significantly lower ACE2 mRNA levels, compared
with current smokers. Multivariable linear regression analysis demonstrated that current smoking and
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COPD are both independently associated with increased ACE2 mRNA expression in lung tissue, even
after adjustment for covariates, including age, sex, body mass index and arterial hypertension (data not
shown).
Through immunohistochemical (IHC) staining, ACE2 protein levels were assessed in lung tissue from 87
subjects. ACE2 IHC revealed positive staining in both bronchial and alveolar epithelial cells, with the latter
predominantly in alveolar type II cells (figure 1b and c). Quantification of ACE2 protein levels in the
alveolar tissue revealed a significantly higher percentage of ACE2-positive alveolar tissue in current
smokers without airflow limitation and current smokers with COPD (GOLD stages II and III–IV)
compared with never-smokers (figure 1b). Moreover, the percentage of ACE2-positive alveolar tissue was
significantly higher in patients with COPD GOLD stage III–IV, compared with ex-smokers without airflow
limitation and ex-smokers with COPD GOLD stage II (figure 1b). Quantification of ACE2 staining in the
bronchial epithelium revealed numerically higher levels in current smokers without airflow limitation and
current smokers with COPD GOLD stage II, and significantly higher levels in patients with COPD GOLD
stage III–IV, compared with never-smokers (figure 1c). Moreover, ACE2 protein levels in the bronchial
epithelium were significantly higher in patients with COPD GOLD stage III–IV, compared with
ex-smokers without airflow limitation and ex-smokers with COPD GOLD stage II (figure 1c). The
observed association between COPD and ACE2 protein expression in alveolar tissue or bronchial
epithelium remained significant after adjustment for possible confounders (data not shown).
As healthcare systems around the world are currently under great pressure due to the COVID-19 outbreak,
identification of those at high risk is crucial. There is compelling evidence of a more severe course of
COVID-19 in smokers and patients with comorbidities such as COPD. We clearly demonstrate an
increased pulmonary expression of the SARS-CoV-2 entry receptor ACE2 in smokers and COPD subjects
at both mRNA and protein level. While our observations complement previous reports on increased ACE2
mRNA and protein levels in whole lung tissue and bronchial epithelium [7–10], this is the first study
demonstrating increased ACE2 protein in the alveolar epithelium of smokers and patients with COPD,
which can be directly linked to the site of injury when patients with severe COVID-19 develop dyspnoea,
hypoxia and pneumonia.
Currently, published data on COVID-19 in patients with COPD is fairly limited [11]. Nevertheless, an
increased risk of developing severe COVID-19 as well as a higher mortality, has been reported in patients
with COPD and in current smokers [3, 12]. Although there are several possible explanations for the
increased susceptibility of severe COVID-19 in patients with COPD, including older age, comorbidities,
dysregulated immune defences and impaired mucociliary clearance, increased pulmonary expression of the
SARS-CoV-2 entry receptor ACE2 is most likely another contributor [13]. Importantly, it has been
demonstrated in mouse models that transgenic (over)expression of human ACE2 enhances the
pathogenicity of SARS-CoV-1 and SARS-CoV-2 [14]. Moreover, human ACE2 was essential for viral
replication in the lung.
The main strength of this study is the large number of lung tissue samples from well-phenotyped subjects
that are included in the RT-PCR and IHC analyses. Moreover, IHC allowed us to quantify ACE2 protein
levels in both bronchial and alveolar epithelium. However, certain limitations should be kept in mind.
First, this study consists mainly of samples from lung resections for pulmonary tumours. This may
introduce selection bias, as altered expression of ACE2 in lung cancer has been suggested [15]. Secondly,
samples of (very) severe COPD originate from a different patient population (lung transplantation), for
which smoking cessation was an inclusion criterium. Finally, as we did not study lung tissue samples from
COVID-19-positive subjects, we can only speculate on the importance of increased ACE2 in the
pathogenicity of SARS-CoV-2.
In conclusion, we report higher ACE2 mRNA and protein levels in lung tissue of smokers and subjects
with moderate-to-(very)-severe COPD. Importantly, ACE2 protein levels are not only increased in
FIGURE 1 Gene and protein expression of angiotensin-converting enzyme 2 (ACE2) in the airways and lungs. a) ACE2 mRNA expression is
increased in the lung tissue of smokers and COPD subjects. ACE2 mRNA expression in the lung tissue of never-, current and ex-smokers without
airflow limitation and current and ex-smokers with moderate (Global Initiative of Chronic Obstructive Lung Disease (GOLD) stage II) or
severe-to-very severe (GOLD stage III–IV) COPD, normalised to the expression of the housekeeping controls glyceraldehyde-3-phosphate
dehydrogenase, peptidylprolyl isomerase A and succinate dehydrogenase complex flavoprotein subunit A. b) ACE2 protein levels are increased in
the alveolar tissue of smokers and COPD subjects. Representative images and quantification of ACE2 immunohistochemical staining in the
alveolar tissue of never-smokers, smokers without airflow limitation, smokers with COPD GOLD stage II and smokers with COPD GOLD stage III–
IV. The area of ACE2-positive signal was normalised to the total area of alveolar tissue present in each analysed image. c) ACE2 protein levels are
increased in the bronchial epithelium of smokers and COPD subjects. Representative images and quantification of ACE2 immunohistochemical
staining in the bronchial epithelium of never-smokers, smokers without airflow limitation and smokers with COPD (GOLD stages II and III–IV). The
area of ACE2-positive signal in each airway was normalised to the length of the basement membrane (Pbm). Data are presented as means±SEM. *:
p<0.05; **: p<0.01; ***: p<0.001.
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bronchial but also in alveolar epithelium. Further research is needed to elucidate whether upregulation of
ACE2 expression in airways and lungs has consequences for the infectivity and clinical outcome of
COVID-19.
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